TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10362188
Drug: High-dose argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose argatroban
Study: 2187701
Drug: Dilevalol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 100 mg once daily
Study: 2187701
Drug: Carteolol 10
Normalized name: carteolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 10 mg once daily
Study: 6500777
Drug: Vincamine teprosilate
Normalized name: vincamine
DrugBank: Vincamine (DB13374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincamine teprosilate (Teproside) administered intravenously (i.v.)
Study: 6500777
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously (i.v.)
Study: 27310969
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) at 5 mg/kg administered at weeks 0, 2, 6, and every 8 weeks thereafter until week 46; dose increased to 10 mg/kg for inadequate responders after week 30
Study: 24047799
Drug: Rotarix vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix vaccine
Study: 22677811
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.3 mg/kg, max. 15 mg)
Study: 22677811
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose of N(2)O (10%)
Study: 16103236
Drug: BQ‐123 (ET-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ‐123 (ET-1 receptor blockade)
Study: 8543520
Drug: Parent- and
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent- and child-administered structured DSM-III-R DISC interviews
Study: 30566363
Drug: Probiotics (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (2.5 × 10^9 CFU/g) containing 9 bacterial strains (Ecologic Barrier)
Study: 29737292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, likely placebo or standard treatment)
Study: 26474430
Drug: Pregabalin (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150-300 mg twice a day)
Study: 23388562
Drug: Paclitaxel poliglumex
Normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel poliglumex (PPX) 50 mg/m/wk with temozolomide 75 mg/m and radiation 2.0 Gy, 5 d/wk for a total dose of 60 Gy
Study: 19496531
Drug: Xenogeneic (mouse)
Normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenogeneic (mouse) gp100 plasmid DNA injected intramuscularly at dosages of 100, 500, or 1,500 microg every three weeks for three doses.
Study: 19496531
Drug: Human gp100
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human gp100 plasmid DNA injected intramuscularly at dosages of 100, 500, or 1,500 microg every three weeks for three doses.
Study: 8121125
Drug: Aspirin (165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (165 mg/day)
Study: 8121125
Drug: Heparin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1000 U/h)
Study: 3478465
Drug: 2% citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% citrate buffered dentifrice in a pluronic gel
Study: 3478465
Drug: Dentifrice containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice containing 0.1% fluoride and 2% citrate buffer in a pluronic gel
Study: 25856785
Drug: ARB +
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB + Hydrochlorothiazide (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Study: 23350826
Drug: Internet-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based treatment programme (124 women)
Study: 23350826
Drug: Postal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postal treatment programme (126 women)
Study: 21295409
Drug: Ivermectin/pyrantel pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin/pyrantel pamoate chewable tablets
Study: 21295409
Drug: Milbemycin oxime
Normalized name: Milbemycin Oxime
DrugBank: Milbemycin oxime (DB11531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milbemycin oxime flavored tablets
Study: 21295409
Drug: Selamectin topical
Normalized name: selamectin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selamectin topical solution
Study: 21295409
Drug: Imidacloprid/moxidectin topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidacloprid/moxidectin topical solution
Study: 19826203
Drug: Shape of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shape of the dose distribution (measured by lateral extent)
Study: 19826203
Drug: Shape of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shape of the dose distribution (measured by longitudinal extent)
Study: 19826203
Drug: Dose-surface histogram
Normalized name: sulfacetamide sodium Ophthalmic Solution [Sulfac]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-surface histogram (DSH)
Study: 19826203
Drug: Shape of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shape of the dose distribution
Study: 16399182
Drug: Stiffer implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stiffer implants (rigidity 1.8)
Study: 16399182
Drug: Regular implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular implants (rigidity 1.0)
Study: 15565453
Drug: Administered dose
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered dose of 0.001 Sv
Study: 11380543
Drug: Oil-in-water (o/w)
Normalized name: water, O-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-in-water (o/w) cream applied 2x/day for 14 days in ICD study
Study: 11380543
Drug: Oil-in-water (o/w)
Normalized name: water, O-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-in-water (o/w) cream applied 2x/day for 4 consecutive days in ACD study
Study: 31026125
Drug: Salt-related knowledge,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt-related knowledge, attitudes, and practices (KAP) intervention; specific details on dosage and duration not available.
Study: 31026125
Drug: Advice to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice to lower salt intake; specific details on dosage and duration not available.
Study: 31026125
Drug: Checking salt/sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checking salt/sodium labels in food; specific details on dosage and duration not available.
Study: 31026125
Drug: Adding extra
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding extra salt to food at the table; specific details on dosage and duration not available.
Study: 31026125
Drug: Reporting high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reporting high amounts of salt consumption; specific details on dosage and duration not available.
Study: 23070341
Drug: Goal-directed lactated
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed lactated Ringer's solution
Study: 23070341
Drug: Goal-directed hydroxyethyl
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed hydroxyethyl starch solution (6% hydroxyethyl starch solution 130/0.4)
Study: 23070341
Drug: Restrictive lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive lactated Ringer's solution
Study: 15812751
Drug: Adriamycin chemotherapy
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin chemotherapy (301 ± 52 mg/m²)
Study: 3153710
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 10 mg/kg
Study: 8547856
Drug: Tryptophan (Trp)
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan (Trp) 1.2 g
Study: 8547856
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Caffeine and Tryptophan (CAF+Trp)
Study: 1493533
Drug: Occlusive dressing
Normalized name: DSG Pak with Occlusive Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusive dressing technique using cream (without silicone oil)
Study: 3991916
Drug: Cimetidine (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.6 g daily) for 24 h before and during the starvation period
Study: 29129441
Drug: Chemotherapy (investigator-choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator-choice platinum-doublet chemotherapy, 4-6 cycles)
Study: 15476516
Drug: OROS-O (controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-O (controlled-release oxybutynin)
Study: 15476516
Drug: IR-O (immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR-O (immediate-release oxybutynin)
Study: 8375632
Drug: Intravesical administration
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical administration of 1 mg oestriol
Study: 24762110
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplementation (1000 mg daily, 5 d/wk for 1 year)
Study: 22467284
Drug: Phase-shifting pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase-shifting pure tone treatment
Study: 22467284
Drug: Pure tone
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure tone treatment without phase shifting
Study: 16124432
Drug: Ivermectin 0.2
Normalized name: ivermectin 0.272 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 0.2 mg/kg for 2 days
Study: 1440822
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg twice daily for 21 days
Study: 11036840
Drug: Intermittent cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclical etidronate therapy
Study: 12610803
Drug: Antirheumatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antirheumatic therapy alone (control)
Study: 10501887
Drug: Hyoscine-N-butylbromide (HB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine-N-butylbromide (HB) 20 mg intraarterially
Study: 8943590
Drug: bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.125% with fentanyl 10 micrograms.ml‐1
Study: 8943590
Drug: bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.125% with diamorphine 125 micrograms.ml‐1
Study: 8943590
Drug: pethidine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: pethidine 2.5 mg.ml‐1
Study: 7034583
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine (0.15 mg)
Study: 30630778
Drug: Delamanid (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delamanid (100 mg twice daily for 2 months followed by 200 mg once daily for 4 months)
Study: 19745649
Drug: Atomoxetine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (80 mg/d)
Study: 16871058
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with morphine (PCA)
Study: 11125723
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy Deferred (CBT-DEF)
Study: 8079104
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole daily at 0800 h (group A)
Study: 8079104
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole every other day (group B)
Study: 178243
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg glucagon intramuscularly
Study: 20966820
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections to confirm trigger sites followed by surgical deactivation
Study: 18318728
Drug: Sequential delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential delivery of 595-nm PDL and 1,064-nm Nd:YAG lasers
Study: 14604019
Drug: 0.65 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 g/kg dose of alcohol
Study: 8797620
Drug: Milrinone (50-micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50-micrograms/kg loading dose, followed by 0.25 microgram/kg/min continuous infusion)
Study: 8797620
Drug: Milrinone (50-micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50-micrograms/kg loading dose, followed by 0.5 microgram/kg/min continuous infusion)
Study: 8797620
Drug: Milrinone (50-micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50-micrograms/kg loading dose, followed by 0.75 microgram/kg/min continuous infusion)
Study: 1626173
Drug: RU486 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU486 (600 mg) followed by Nalador (intravenous sulprostone)
Study: 28215130
Drug: Intravenous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GLP-1 (1.2 pmol/kg/min)
Study: 19122353
Drug: Exercise advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise advice and prescription, dietary instructions
Study: 11843382
Drug: Progestogen-only oral
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen-only oral contraceptives and progesterone vaginal ring
Study: 9760010
Drug: Lubeluzole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 2.5 mg, 5 mg, and 10 mg
Study: 9760010
Drug: Lubeluzole 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 15 mg, 20 mg, and 25 mg
Study: 7930388
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) stimulation with arginine (0.5 g/kg bw) and recombinant GH (4 IU im) in Group 2 (normal IGF-I range)
Study: 7930388
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) stimulation with arginine (0.5 g/kg bw) and recombinant GH (4 IU im) in Group 1 (abnormally low IGF-I concentration)
Study: 23439168
Drug: Stepwise self-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise self-titration of oral glucose-lowering medication with self-monitoring and remote nurse monitoring
Study: 23439168
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group patients changing their oral glucose-lowering medication
Study: 23439168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group patients changing their oral glucose-lowering medication
Study: 20528837
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg thiamylal
Study: 3877474
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg propofol
Study: 17562958
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of autologous CD34+ stem cells
Study: 15486408
Drug: Sitaxsentan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan (100 mg/d)
Study: 30041587
Drug: Medications acknowledged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications acknowledged in PCP record
Study: 21126127
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg plus low dose aspirin (LDA), n = 30
Study: 21126127
Drug: Enoxaparin 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20 mg plus LDA, n = 30
Study: 7582386
Drug: Bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 400 mg once a day
Study: 16497101
Drug: Goeckerman's therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goeckerman's therapy (GT) including dermal application of crude coal tar and exposure to UV radiation
Study: 17221216
Drug: Goeckerman's therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goeckerman's therapy (GT)
Study: 14571257
Drug: Oral D-amphetamine
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D-amphetamine (AMPH) 30 mg
Study: 9894373
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil (adjustable to 100 mg or 25 mg based on efficacy and tolerability)
Study: 22211208
Drug: Web-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based intervention featuring actors simulating a patient discussing treatment concerns (N=24)
Study: 22211208
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group shown an educational video about schizophrenia treatment (N=26)
Study: 9381445
Drug: Letter arguing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letter arguing for reduction of daily benzodiazepine intake
Study: 8410962
Drug: alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam (1 mg) and alcohol (0.5 g/kg)
Study: 8410962
Drug: alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam (1 mg) and placebo drink
Study: 8410962
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule and alcohol (0.5 g/kg)
Study: 8410962
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule and placebo drink
Study: 27864822
Drug: Home‐based hand‐arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home‐based hand‐arm bimanual intensive therapy (H‐HABIT; n=12)
Study: 19324530
Drug: oxcarbazepine (1,000‐2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxcarbazepine (1,000‐2,400 mg/day)
Study: 19324530
Drug: divalproex (750‐2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: divalproex (750‐2,000 mg/day)
Study: 17684201
Drug: DHA oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA oil (7.5 g DHA oil/d, equivalent to 3 g DHA/d)
Study: 10088202
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg once a day for 4 weeks
Study: 10088202
Drug: Metoprolol 95
Normalized name: metoprolol 95 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 95 mg once a day for 4 weeks
Study: 7529981
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day prednisolone
Study: 7529981
Drug: 5.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/day prednisolone
Study: 29141124
Drug: Overall Valbenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall Valbenazine treatment
Study: 23374797
Drug: Fenoldopam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (0.1 μg/kg/min for 24 hours)
Study: 19650803
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block (FIC) with 30 ml of ropivacaine 3.75 mg/ml (112.5 mg) 20 min before spinal block
Study: 19650803
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia with alfentanil (IVA) - bolus dose of 10 microg/kg, continuous infusion of 0.25 microg/kg/min starting 2 min before spinal block
Study: 19650803
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia with alfentanil (IVA)
Study: 15209007
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly iron supplementation
Study: 9971864
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfusions if hemoglobin < 7.0 g/dL, maintained at 7.0 to 9.0 g/dL)
Study: 9971864
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusions if hemoglobin < 10.0 g/dL, maintained at 10.0 to 12.0 g/dL)
Study: 6932992
Drug: BCG and
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG and monthly chemotherapy
Study: 6932992
Drug: Weekly irradiated
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly irradiated allogeneic blast cells
Study: 31156155
Drug: Regular +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular + NPH Insulin
Study: 31156155
Drug: Novo‐rapid +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novo‐rapid + Levemir Insulin
Study: 28973074
Drug: SAbR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAbR plus maintenance chemotherapy
Study: 20223094
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1000 mg/day)
Study: 10223757
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (1 to 2 ml of 2 percent lignocaine) during triple rubber band ligation
Study: 10223757
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no local anesthetic injection) during triple rubber band ligation
Study: 8847153
Drug: Brodimoprim 400
Normalized name: brodimoprim
DrugBank: Brodimoprim (DB13795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim 400 mg OD on the first day followed by 200 mg OD for 2 days
Study: 8847153
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg BID
Study: 25733630
Drug: Hookworm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hookworm treatment
Study: 28534476
Drug: Conventional directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional directly observed therapy (DOT)